Europe - Euronext Milan - BIT:1FRE - DE0005785604 - Common Stock
The current stock price of 1FRE.MI is 46.46 EUR. In the past month the price increased by 72.27%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| FRE.DE | FRESENIUS SE & CO KGAA | 13.9 | 26.70B | ||
| FME.DE | FRESENIUS MEDICAL CARE AG | 10.49 | 23.14B | ||
| V3V.DE | FAMICORD AG | 38.93 | 96.14M |
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. The company is headquartered in Bad Homburg, Hessen and currently employs 176,207 full-time employees. The firm has operationally managed divisions Fresenius Kabi and Fresenius Helios as well as the holdings Fresenius Vamed and Fresenius Medical Care. Fresenius Kabi offers healthcare products for critically and chronically ill patients and offers essential medicines and medical technology for infusion, transfusion and clinical nutrition and its product portfolio includes intravenously administered generic medicines, infusion therapies and clinical nutrition. Fresenius Helios is a private hospital operator that operates clinics, medical facilities, rehabilitation centers and others. Fresenius Vamed provides services for hospitals and other healthcare facilities such as prevention, construction, service and operational management. Fresenius Medical Care offers products and services along the dialysis value chain and is a supplier of dialysis products such as dialysis machines, dialyzers and associated disposable accessories.
FRESENIUS SE & CO KGAA
Else-Kroener-Str. 1
BAD HOMBURG HESSEN DE
Employees: 176207
Phone: 4961726080
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. The company is headquartered in Bad Homburg, Hessen and currently employs 176,207 full-time employees. The firm has operationally managed divisions Fresenius Kabi and Fresenius Helios as well as the holdings Fresenius Vamed and Fresenius Medical Care. Fresenius Kabi offers healthcare products for critically and chronically ill patients and offers essential medicines and medical technology for infusion, transfusion and clinical nutrition and its product portfolio includes intravenously administered generic medicines, infusion therapies and clinical nutrition. Fresenius Helios is a private hospital operator that operates clinics, medical facilities, rehabilitation centers and others. Fresenius Vamed provides services for hospitals and other healthcare facilities such as prevention, construction, service and operational management. Fresenius Medical Care offers products and services along the dialysis value chain and is a supplier of dialysis products such as dialysis machines, dialyzers and associated disposable accessories.
The current stock price of 1FRE.MI is 46.46 EUR. The price increased by 0.61% in the last trading session.
FRESENIUS SE & CO KGAA (1FRE.MI) has a dividend yield of 2.12%. The yearly dividend amount is currently 0.
1FRE.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
FRESENIUS SE & CO KGAA (1FRE.MI) operates in the Health Care sector and the Health Care Providers & Services industry.
The Revenue of FRESENIUS SE & CO KGAA (1FRE.MI) is expected to grow by 4.78% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
You can find the ownership structure of FRESENIUS SE & CO KGAA (1FRE.MI) on the Ownership tab.
ChartMill assigns a technical rating of 3 / 10 to 1FRE.MI.
ChartMill assigns a fundamental rating of 4 / 10 to 1FRE.MI. Both the profitability and the financial health of 1FRE.MI get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months 1FRE.MI reported a non-GAAP Earnings per Share(EPS) of 3.27. The EPS increased by 1090.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 5.06% | ||
| ROA | 2.72% | ||
| ROE | 6.15% | ||
| Debt/Equity | 0.61 |
23 analysts have analysed 1FRE.MI and the average price target is 51.21 EUR. This implies a price increase of 10.23% is expected in the next year compared to the current price of 46.46.
For the next year, analysts expect an EPS growth of 13.47% and a revenue growth 4.78% for 1FRE.MI